Paeonol alleviates atherosclerosis by inhibiting CD8+ T-cell activation via targeting the SYK/NFATc1 signaling pathway in ApoE-/- mice - PubMed
6 hours ago
- #Atherosclerosis
- #Paeonol
- #CD8+ T-cell
- Paeonol (Pae), a bioactive compound from Moutan Cortex, alleviates atherosclerosis by inhibiting CD8+ T-cell activation.
- The study investigated Pae's role in targeting the SYK/NFATc1 signaling pathway to reduce CD8+ T-cell activation and vascular endothelial cell injury.
- Experiments were conducted on high-fat diet-fed ApoE-/- mice treated with Pae or simvastatin for 4 weeks.
- Pae attenuated atherosclerotic plaque formation and reduced SYK phosphorylation, NFATc1 nuclear translocation, and cytotoxic mediator release in CD8+ T-cells.
- Pae directly targets SYK, and SYK overexpression negated Pae's protective effects.
- Pae also reduced vascular endothelial cell injury caused by CD8+ T-cell-conditioned medium.
- The findings suggest SYK in CD8+ T-cells as a potential therapeutic target for atherosclerosis.